NASDAQ:BOLT Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $0.66 +0.02 (+3.13%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrends About Bolt Biotherapeutics Stock (NASDAQ:BOLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bolt Biotherapeutics alerts:Sign Up Key Stats Today's Range$0.64▼$0.6650-Day Range$0.58▼$0.6952-Week Range$0.55▼$1.56Volume24,440 shsAverage Volume168,994 shsMarket Capitalization$25.20 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingHold Company OverviewBolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Read More… Elon knows the truth, which is why they want him silenced (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Bolt Biotherapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks54th Percentile Overall ScoreBOLT MarketRank™: Bolt Biotherapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 356th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingBolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Bolt Biotherapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.52) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bolt Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.46% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently increased by 0.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth.Read more about Bolt Biotherapeutics' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.46% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently increased by 0.34%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for BOLT on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.90% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bolt Biotherapeutics' insider trading history. Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BOLT Stock News HeadlinesBy popular demand, Epiphone brings back the Mike Dirnt and Gene Simmons-approved Grabber BassSeptember 27, 2024 | msn.comOncology Institute (NASDAQ:TOI) Stock Quotes, Forecast and News SummarySeptember 23, 2024 | benzinga.comEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.November 2, 2024 | Paradigm Press (Ad)Bolt Biotherapeutics Announces Changes to its Board of DirectorsSeptember 4, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLTSeptember 3, 2024 | prnewswire.comBOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 3, 2024 | prnewswire.comBOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their RightsSeptember 2, 2024 | businesswire.comBOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 2, 2024 | globenewswire.comSee More Headlines BOLT Stock Analysis - Frequently Asked Questions How have BOLT shares performed this year? Bolt Biotherapeutics' stock was trading at $1.12 at the beginning of 2024. Since then, BOLT shares have decreased by 41.2% and is now trading at $0.6585. View the best growth stocks for 2024 here. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its earnings results on Tuesday, August, 13th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.08. The company had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.19 million. Bolt Biotherapeutics had a negative net margin of 592.57% and a negative trailing twelve-month return on equity of 61.40%. When did Bolt Biotherapeutics IPO? Bolt Biotherapeutics (BOLT) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Athenex (ATNX), NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPeng (XPEV). Company Calendar Last Earnings8/13/2024Today11/02/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLT CUSIP09769810 CIK354655 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$8.00 Low Stock Price Target$1.00 Potential Upside/Downside+431.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,200,000.00 Net Margins-592.57% Pretax Margin-592.57% Return on Equity-61.40% Return on Assets-43.95% Debt Debt-to-Equity Ratio0.19 Current Ratio4.28 Quick Ratio4.28 Sales & Book Value Annual Sales$11.17 million Price / Sales2.26 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book0.22Miscellaneous Outstanding Shares38,265,000Free Float26,441,000Market Cap$25.20 million OptionableNot Optionable Beta0.93 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:BOLT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.